Skip to main content
. Author manuscript; available in PMC: 2020 Sep 25.
Published in final edited form as: Biol Blood Marrow Transplant. 2018 Jun 15;24(10):2133–2138. doi: 10.1016/j.bbmt.2018.06.009

Table 5:

Pre-treatment risk factors associated with OS in multivariate analysis (N=60)

Number of PFS risk factors 3y OS HR for progression (95% CI)

0 (relapsed, AA I-II, N=25) 79%
1 (primary refractory or AA* III-IV, N=26) 58% 2.68 (1.04, 6.91)
2 (primary refractory and AA III-IV, N=9) 22% 6.86 (2.27, 20.8)
*

AA = Ann Arbor stage